Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold
The US FDA appears to have concerns about the device used to administer the vaccine.
You may also be interested in...
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.